Cash Flow Statement

Altimmune (ALT) Gains from Investment Securities (2016 - 2025)

Altimmune (ALT) has disclosed Gains from Investment Securities for 13 consecutive years, with $25000.0 as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities rose 1150.0% to $25000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $494000.0 through Dec 2025, up 137.68% year-over-year, with the annual reading at $794740.0 for FY2025, 88.01% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was $25000.0 at Altimmune, down from $2.7 million in the prior quarter.
  • The five-year high for Gains from Investment Securities was $8.4 million in Q1 2025, with the low at -$1.8 million in Q1 2022.
  • Average Gains from Investment Securities over 5 years is $2.3 million, with a median of $1.7 million recorded in 2021.
  • Peak annual rise in Gains from Investment Securities hit 22302.09% in 2022, while the deepest fall reached 302.27% in 2022.
  • Over 5 years, Gains from Investment Securities stood at -$860000.0 in 2021, then skyrocketed by 150.0% to $430000.0 in 2022, then tumbled by 91.4% to $37000.0 in 2023, then tumbled by 94.59% to $2000.0 in 2024, then skyrocketed by 1150.0% to $25000.0 in 2025.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at $25000.0, $2.7 million, and $478995.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.